Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes

Area of Science:

• Oncolytic virotherapy
• Cancer research
• Immunology

Background:

• Oncolytic adenoviruses show promise for cancer therapy.
• Systemic delivery faces challenges like neutralizing antibodies.
• Chimeric adenovirus Ad5/3 is a potential therapeutic agent.

Purpose of the Study:

• To investigate the interaction of chimeric adenovirus Ad5/3 with human lymphocytes and erythrocytes.
• To understand the mechanism of tumor transduction in the presence of neutralizing antibodies.
• To evaluate the impact of Ad5/3 binding to blood cells on tumor targeting and oncolytic potency.

Main Methods:

• In vitro and in vivo studies using chimeric adenovirus Ad5/3.
• Analysis of Ad5/3 binding kinetics with human lymphocytes and erythrocytes.
• Assessment of tumor transduction and oncolytic efficacy in immunodeficient mice bearing xenograft tumors.

Main Results:

• Ad5/3 demonstrated reversible binding to human lymphocytes and erythrocytes.
• This binding facilitated viral transduction of tumors.
• Systemic administration of Ad5/3 bound to blood cells enhanced tumor transduction in vivo, even with neutralizing antibodies.
• Ad5/3 exhibited oncolytic potency in vitro and in vivo.

Conclusions:

• Chimeric Ad5/3 adenovirus can effectively reach non-injected tumors despite the presence of neutralizing antibodies.
• Reversible binding to lymphocytes and erythrocytes is a key mechanism for Ad5/3 tumor targeting.
• This interaction enhances the therapeutic potential of oncolytic adenoviruses in cancer treatment.